Article

Alcon proceeds with WaveLight deal

Alcon Inc. had gained control of 76.9% of WaveLight's approximately 6.6 million issued and outstanding shares as of Sept. 28.

Huenenberg, Switzlerland-Alcon Inc. had gained control of 76.9% of WaveLight's approximately 6.6 million issued and outstanding shares as of Sept. 28. The German Security Purchase and Take-over Act also required an additional 2-week acceptance period, Sept. 29 to Oct. 12, during which time Alcon expected to acquire additional shares from WaveLight shareholders.

The company received approvals from the competition authorities in Germany and Austria and was awaiting cartel clearances in China, Cyprus, and Spain prior to closing of the transaction.

"Once we obtain the other regulatory approvals, we can begin the process of integrating WaveLight with Alcon's existing refractive business," said Cary Rayment, Alcon's chairman, president, and chief executive officer (CEO).

Through Sept. 25, about 3.1 million WaveLight shares were tendered to Alcon, equal to 47.1% of the issued and outstanding WaveLight shares. Additionally, Alcon legally acquired 1.96 million WaveLight shares, or 29.9% of the issued and outstanding shares, either on the stock market or through direct purchase.

"Alcon's friendly takeover offer is in the best interest of WaveLight shareholders. I am glad that the offer reached such a high level of acceptance," said Max Reindl, WaveLight's CEO.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.